Initiator Pharma to present at Nordic Women's Health Hub 2025

Initiator Pharma A/S, a clinical-stage biotech company, today announces that its CEO, Claus Elsborg Olesen, will present and together with Julia Persson, Founder of HappyLongevity and AI-Augmented Venture Designer, co-lead a session focused on health innovation at the upcoming Nordic Women's Health Hub, taking place on September 8, 2025, 10.00–17.00 at Fællessalen, Christiansborg, Copenhagen, Denmark.

Initiator Pharma's participation highlights the company's strong focus on female health and commitment to addressing areas of high unmet medical need. Recently, Initiator Pharma announced that it has applied to initiate a Phase 2a clinical proof-of-concept study evaluating pudafensine in women suffering from vulvodynia, a severe chronic pain condition affecting approximately 10 percent of women worldwide.

"Women's health has long been underserved in medical research, and conditions such as vulvodynia are often underdiagnosed and undertreated despite their profound impact on quality of life. At Initiator Pharma, we are committed to changing this by developing innovative treatments that address these unmet needs. The Nordic Women's Health Hub is an important platform to raise awareness, foster dialogue, and drive collaboration across stakeholders to improve women's health outcomes," said Claus Elsborg Olesen, CEO of Initiator Pharma.

The Nordic Women's Health Hub is a dedicated forum for advancing women's health by bringing together researchers, industry leaders, healthcare professionals, and policymakers. More information about the event can be found at **nordicwomenshealth.com**.

For additional information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma
Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma's pipeline consists of two clinical stage assets – pudafensine and IP2018 – and one preclinical asset. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED as well as in a clinical proof-of-principle study in a capsaicin challenge pain trial. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company's Certified Adviser. For more information, please visit www.initiatorpharma.com.

About vulvodynia
Vulvodynia is a chronic pain condition that affects the vulva. Vulvodynia affects approximately 10% of all women worldwide. Clinically, vulvodynia is defined as chronic vulvar pain lasting at least three months without a clearly identifiable cause.
Besides pain, vulvodynia patients also have impaired sexual function. Women living with vulvodynia experience excruciating pain during routine activities such as walking, sitting or even wearing tight-fitting pants. Many are unable to use tampons or engage in sexual activities. All this profoundly

affects their quality of life and partner relationship.
Current therapies are off-label, frequently inadequate, and often accompanied by undesirable side effects. Therefore physicians face significant challenges in addressing vulvodynia and the patients are treated with a multitude of therapies on a trial and error basis. The economic burden of vulvodynia is substantial. Patients often try multiple health care providers and ineffective therapies in their search for a diagnosis and a cure, leading to wasted healthcare expenditures and escalating costs.

About pudafensine (IP2015)
Pudafensine, Initiators Pharma's most advanced asset, is a monoamine reuptake inhibitor that preferentially inhibits the synaptic reuptake of dopamine followed by serotonin thereby increasing the levels of dopamine in the synapses. Pudafensine is being developed for both organic Erectile Dysfunction (ED), Female Sexual Dysfunction and pain indications. The treatment is expected to improve the quality of life for many patients who are not responding to or cannot be treated with existing drugs on the market.

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: **ceo@initiatorpharma.com**

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma's pipeline consists of two clinical stage assets – pudafensine and IP2018 – and one preclinical asset. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company's Certified Adviser. For more information, please visit **www.initiatorpharma.com.**

About vulvodnia

Vulvodynia is a chronic pain condition that affects the vulva. Vulvodynia affects approximately 10% of all women worldwide. Clinically, vulvodynia is defined as chronic vulvar pain lasting at least three months without a clearly identifiable cause.
Besides pain, vulvodynia patients also have impaired sexual function. Women living with vulvodynia experience excruciating pain during routine activities such as walking, sitting or even wearing tight-fitting pants. Many are unable to use tampons or engage in sexual activities. All this profoundly affects their quality of life and partner relationship.
Current therapies are off-label, frequently inadequate, and often accompanied by undesirable side effects. Therefore physicians face significant challenges in addressing vulvodynia and the patients are treated with a multitude of therapies on a trial and error basis.The economic burden of vulvodynia is substantial. Patients often try multiple health care providers and ineffective therapies in their search for a diagnosis and a cure, leading to wasted healthcare expenditures and escalating costs.

About pudafensine

Pudafensine, Initiators Pharma's most advanced asset, is a monoamine reuptake inhibitor that preferentially inhibits the synaptic reuptake of dopamine followed by serotonin thereby increasing the levels of dopamine in the synapses. Pudafensine is being developed for both organic Erectile Dysfunction (ED), Female Sexual Dysfunction and pain indications. The treatment is expected to improve the quality of life for many patients who are not responding to or cannot be treated with existing drugs on the market.

Attachments

Initiator Pharma to present at Nordic Women's Health Hub 2025